{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/corticosteroids-topical-skin-nose-eyes/management/intranasal-corticosteroid-treatment/","result":{"pageContext":{"chapter":{"id":"520275be-3f1d-5e10-8de2-5524f170f2ba","slug":"intranasal-corticosteroid-treatment","fullItemName":"Scenario: Intranasal corticosteroid treatment","depth":2,"htmlHeader":"<!-- begin field 4f18c23a-907a-438f-bdd1-7413603f0cc0 --><h2>Scenario: Intranasal corticosteroid treatment</h2><!-- end field 4f18c23a-907a-438f-bdd1-7413603f0cc0 -->","summary":"Covers the management of people receiving intranasal corticosteroids in primary care.","htmlStringContent":"<!-- begin item a93ac268-2b29-43ef-a166-697a0bda37ef --><!-- begin field 015d8aa4-fa73-4eeb-a697-acd900ab0ce4 --><p>From birth onwards.</p><!-- end field 015d8aa4-fa73-4eeb-a697-acd900ab0ce4 --><!-- end item a93ac268-2b29-43ef-a166-697a0bda37ef -->","topic":{"id":"091d926b-472d-55aa-b732-215f8299eb6e","topicId":"fe2967bf-dc0e-4dd2-903c-812a35c0d510","topicName":"Corticosteroids - topical (skin), nose, and eyes","slug":"corticosteroids-topical-skin-nose-eyes","lastRevised":"Last revised in September 2020","chapters":[{"id":"d7e6a05a-1ad6-5002-9e1d-418bb0509a7e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"30c29984-be54-5cc7-b45b-ccea8330c500","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"01ed2c05-1414-51dd-85da-6ddc4bbc005d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"791cb5ff-e017-51d6-b7ee-cabacb293b82","slug":"changes","fullItemName":"Changes"},{"id":"110d5d5e-8e14-51d5-ab15-5afa0d551cf7","slug":"update","fullItemName":"Update"}]},{"id":"6481ae53-8731-5bbf-84bb-f9c18452558f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"746ed409-c3cc-5d5f-a043-6c7e517b0f61","slug":"goals","fullItemName":"Goals"},{"id":"40ab5ace-33b8-5a2c-a6bb-cbd7fe8ca07c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc1a105d-dd83-5e54-b930-588a3dbdb5cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f6a0228b-0765-5b1b-b1b7-25eca749a1ab","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"842d280b-d84c-5903-bbdb-3f4fe26412fc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"17589721-7493-5da3-8828-e2b4bec649b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e1a50e32-af60-5677-ad61-93b4be058bdd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e28586d8-7d65-5f08-a10b-d2d25b975112","slug":"definition","fullItemName":"Definition"},{"id":"58a9256e-a859-56a0-a7a3-946a224e6310","slug":"action-of-local-corticosteroids","fullItemName":"Action of local corticosteroids"},{"id":"8e053a89-aa32-5f75-aefc-61b421905b9d","slug":"availability","fullItemName":"Availability"}]},{"id":"1967c89c-d7ce-51d0-a539-3bf6738b65b4","fullItemName":"Management","slug":"management","subChapters":[{"id":"b60ad525-96a0-5836-9db8-d24fc5c18423","slug":"topical-treatment","fullItemName":"Scenario: Topical treatment"},{"id":"520275be-3f1d-5e10-8de2-5524f170f2ba","slug":"intranasal-corticosteroid-treatment","fullItemName":"Scenario: Intranasal corticosteroid treatment"},{"id":"f718a357-8e9a-50d8-ad33-87c1b4345715","slug":"eye-treatment","fullItemName":"Scenario: Eye treatment"}]},{"id":"ebd50a03-95ac-50a9-8a2d-4d615c9569bb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0620ec75-3526-5198-b134-4f31d225ab30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2b03e883-8770-59d5-9965-04ffada0e471","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73e06218-1739-5de2-908f-ba65ba970168","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f813f700-2fb0-5989-90bd-2c2aa6dbb85a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3aa0e05-0446-53c0-9de1-2a8d2a9d1a70","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2a6ead30-5d09-5a96-b6d4-b673b755b98a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e78ffc84-8544-5685-8a35-65c8f05aac92","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1967c89c-d7ce-51d0-a539-3bf6738b65b4","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"9c000000-2c56-58c0-852c-8e7153f97e72","slug":"initiation","fullItemName":"Initiation","depth":3,"htmlHeader":"<!-- begin field 216ff74c-c2c3-4eb1-bd47-a2b6b59091bf --><h3>What should I consider when initiating intranasal corticosteroids?</h3><!-- end field 216ff74c-c2c3-4eb1-bd47-a2b6b59091bf -->","summary":null,"htmlStringContent":"<!-- begin item a3ad3837-8065-4fe4-ba77-9141a2c888bc --><!-- begin field c951f247-d5ab-40e0-a8f7-f7ea9bd156e6 --><ul><li>Intranasal corticosteroids are available as drops and sprays. The risk of systemic adverse effects is greater with drops (as they are more likely to be administered incorrectly, resulting in greater systemic bioavailability of the corticosteroid). </li><li>The intranasal corticosteroids that are available in the UK are equally effective.<ul><li>However, for children, consider prescribing a preparation other than twice-daily beclometasone, which may suppress growth more than other intranasal corticosteroids (such as fluticasone, mometasone, or triamcinolone). Nevertheless, prolonged treatment with other corticosteroid preparations has the potential to suppress growth in children. <ul><li>Monitor the height of children receiving prolonged treatment with intranasal corticosteroids. If growth suppression is suspected, consider referral to a paediatrician.</li></ul></li></ul></li></ul><!-- end field c951f247-d5ab-40e0-a8f7-f7ea9bd156e6 --><!-- end item a3ad3837-8065-4fe4-ba77-9141a2c888bc -->","subChapters":[{"id":"9dc464a7-2001-5790-814a-f153fc385b6c","slug":"basis-for-recommendation-811","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a7e65603-9b99-4efb-ae8c-af6a5a2a79f7 --><h4>Basis for recommendation</h4><!-- end field a7e65603-9b99-4efb-ae8c-af6a5a2a79f7 -->","summary":null,"htmlStringContent":"<!-- begin item 811a976f-afb3-4ca5-8f7f-4f83ca2c8a8c --><!-- begin field 36039b16-9795-44b3-b07a-76e198870f0c --><p>These recommendations are largely based on the British Society of Allergy and Clinical Immunology (BSACI) <em>BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (revised edition 2017; first edition 2007)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Scadding, 2017</a>], the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>], and a Cochrane systematic review <em>Different types of intranasal steroids for chronic rhinosinusitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Chong et al, 2016</a>].</p><h5>Choosing an intranasal corticosteroid</h5><ul><li>A Cochrane systematic review that assessed the effects of different types of intranasal steroids in people with chronic rhinosinusitis found insufficient evidence to suggest that one type of intranasal steroid is more effective than another in patients with chronic rhinosinusitis, nor that the effectiveness of a spray differs from an aerosol. No studies were identified that compared drops with spray [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Chong et al, 2016</a>]. </li><li>There is similar clinical efficacy for all intranasal corticosteroids, but bioavailability varies considerably. Factors that need to be considered when choosing an intranasal corticosteroid include systemic drug bioavailability, safety, cost, and ease of device use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Scadding, 2017</a>]. </li></ul><h5>Intranasal corticosteroids and growth suppression in children</h5><ul><li>Systemic absorption is negligible with mometasone furoate and fluticasone furoate, modest for other corticosteroids, and highest for betamethasone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Scadding, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].<ul><li>Mometasone and fluticasone are favoured for use in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Scadding, 2017</a>].</li></ul></li><li>Several small studies have compared intranasal corticosteroids with placebo in children with allergic rhinitis.<ul><li>These studies show that twice daily beclometasone can slow growth velocity in children, whilst once daily mometasone, triamcinolone, fluticasone, and budesonide do not affect growth. However, it is not known whether once daily beclometasone also affects growth [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Schenkel, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Skoner, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Allen, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Ober, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Murphy, 2006</a>].</li></ul></li><li>However, other studies have shown that, over a 12-month period, the use of once daily fluticasone in children aged 5–8 years (n = 186) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Lee, 2014</a>], and once daily triamcinolone in children aged 3–9 years (n = 1078) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Skoner, 2015</a>], may result in a small reduction in growth velocity. </li><li>The height of children receiving prolonged treatment with intranasal corticosteroids should be monitored. If growth suppression is suspected, referral to a paediatrician should be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].</li></ul><!-- end field 36039b16-9795-44b3-b07a-76e198870f0c --><!-- end item 811a976f-afb3-4ca5-8f7f-4f83ca2c8a8c -->","subChapters":[]}]},{"id":"1e72e6d6-52be-5a1b-8dde-4dbf415bd9b1","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field 0407c91c-978b-408f-bbdc-a74a00f45aca --><h3>What contraindications are associated with intranasal corticosteroids?</h3><!-- end field 0407c91c-978b-408f-bbdc-a74a00f45aca -->","summary":null,"htmlStringContent":"<!-- begin item 80371067-e348-4387-b8d6-a74a00f458c8 --><!-- begin field 2106efd1-d83c-46c0-a536-a74a00f45aca --><ul><li>Do not prescribe intranasal corticosteroids to people:<ul><li>With untreated fungal, bacterial, or viral nasal infections. </li><li>After recent nasal surgery, or trauma, unless on specialist advice. <ul><li>Intranasal corticosteroids can be used <em>after </em>healing has occurred.</li></ul></li><li>Pulmonary tuberculosis. </li></ul></li></ul><!-- end field 2106efd1-d83c-46c0-a536-a74a00f45aca --><!-- end item 80371067-e348-4387-b8d6-a74a00f458c8 -->","subChapters":[{"id":"773dbb01-924f-5ea2-98f3-d5ff4b1d5c93","slug":"basis-for-recommendation-2fb","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fe07ba08-c63a-4a5d-86fe-a74a00f45aca --><h4>Basis for recommendation</h4><!-- end field fe07ba08-c63a-4a5d-86fe-a74a00f45aca -->","summary":null,"htmlStringContent":"<!-- begin item 2fb89b04-e343-4fc1-b971-a74a00f45aca --><!-- begin field 0cbb9d5a-2fb2-48e6-9486-a74a00f45aca --><p>These recommendations are based on the <em>British National Formular</em>y (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>] and the manufacturers' summaries of product characteristics for Flixonase [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019b</a>], Beconase [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019a</a>], and Nasonex [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2020c</a>].</p><!-- end field 0cbb9d5a-2fb2-48e6-9486-a74a00f45aca --><!-- end item 2fb89b04-e343-4fc1-b971-a74a00f45aca -->","subChapters":[]}]},{"id":"2a99b13b-652d-5715-91e9-b885bcb86068","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field e5eb629e-a314-48fc-955a-a74a00f46f5b --><h3>Can I prescribe intranasal corticosteroids to a woman who is pregnant or breastfeeding?</h3><!-- end field e5eb629e-a314-48fc-955a-a74a00f46f5b -->","summary":null,"htmlStringContent":"<!-- begin item 12d9123c-9268-4b3b-af64-a74a00f46f02 --><!-- begin field cd88320e-f497-4aa3-9f3b-a74a00f46f5b --><ul><li><strong>Pregnancy</strong><ul><li>Intranasal corticosteroids can be used in pregnancy.</li></ul></li><li><strong>Breastfeeding</strong><ul><li>Intranasal corticosteroids can be used during breastfeeding.</li></ul></li></ul><!-- end field cd88320e-f497-4aa3-9f3b-a74a00f46f5b --><!-- end item 12d9123c-9268-4b3b-af64-a74a00f46f02 -->","subChapters":[{"id":"f5f1ea86-18ee-5669-8502-dde441776f50","slug":"basis-for-recommendation-f6f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 98ec1494-bc30-4609-bb5d-a74a00f46f5f --><h4>Basis for recommendation</h4><!-- end field 98ec1494-bc30-4609-bb5d-a74a00f46f5f -->","summary":null,"htmlStringContent":"<!-- begin item f6fe32d7-c3e6-4012-a5ff-a74a00f46f5f --><!-- begin field 8552057a-c8b8-4f9d-85ed-a74a00f46f5f --><h5>Pregnancy</h5><ul><li>This recommendation is based on the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>], manufacturer's summaries of product characteristics, the UK Teratology Information Service (UKTIS) monograph <em>Corticosteroids in pregnancy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">UKTIS, 2016b</a>], and a systematic review <em>Safety of intranasal corticosteroid sprays during pregnancy: an updated review</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Alhussien, 2017</a>]. <ul><li>A systematic review found no significant link with congenital organ malformations and intranasal use of beclomethasone, budesonide, fluticasone propionate, fluticasone furoate, or mometasone. However, intranasal triamcinolone was found to have a significant association with respiratory tract defects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Alhussien, 2017</a>]. </li><li>Manufacturers of Beconase, Flixonase, and Nasonex advise that there is inadequate evidence of safety in human pregnancy and highlight an association between relatively high systemic exposure and birth defects in animals, however, they state that direct intranasal application ensures minimal systemic exposure, but they should not be used unless the potential benefits outweigh the possible risks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2020c</a>]. </li><li>The UKTIS monograph on oral corticosteroids states that currently available data do not suggest that first trimester exposure to systemic corticosteroids in pregnancy increases the overall risk of congenital abnormalities, such as cleft lip/palate [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">UKTIS, 2016b</a>]. </li></ul></li></ul><h5>Breastfeeding</h5><ul><li>This recommendation is based on the Specialist Pharmacy Service (SPS) document <em>Safety in lactation: drugs used in nasal allergy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">SPS, 2016b</a>], the Drugs and Lactation Database (LactMed), and manufacturer's summaries of product characteristics for Beconase, Flixonase, and Nasonex.<ul><li>Drugs used for nasal allergy have limited systemic absorption in the mother, and pose negligible risk to a breastfed infant. There is no published evidence of safety or milk levels for any of the listed drugs when used intranasally [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">SPS, 2016b</a>].</li><li>The amounts of inhaled and nasal corticosteroids absorbed into the maternal bloodstream and excreted into breastmilk are probably too small to affect a breastfed infant [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">LactMed, 2020</a>]. </li><li>Manufacturers of Beconase [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019a</a>] and Flixonase [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019b</a>] advise that there is low potential for significant levels in breast milk, while the manufacturer of Nasonex [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2020c</a>] advises that a decision must be made whether to discontinue breastfeeding or to discontinue Nasonex, taking into account the benefits of breastfeeding for the child and the benefit of therapy for the woman.</li></ul></li></ul><!-- end field 8552057a-c8b8-4f9d-85ed-a74a00f46f5f --><!-- end item f6fe32d7-c3e6-4012-a5ff-a74a00f46f5f -->","subChapters":[]}]},{"id":"6dfd7fe0-0aa8-5d90-8bc9-bb47ae2c0845","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field b74809a2-9ea3-41f1-86e1-a74a00f484da --><h3>What are the adverse effects of intranasal corticosteroids?</h3><!-- end field b74809a2-9ea3-41f1-86e1-a74a00f484da -->","summary":null,"htmlStringContent":"<!-- begin item 2b7fc310-196b-4876-bfc9-a74a00f48464 --><!-- begin field 3d34d20c-4e93-4c8a-9e1c-a74a00f484da --><ul><li><strong>Local adverse effects of intranasal corticosteroids include: </strong><ul><li>Nasal dryness, irritation, and nosebleeds.</li><li>Throat dryness, throat irritation.</li><li>Skin erythema, rash, itching.</li><li>Headache, disturbance of smell and taste.</li><li>Nasal burning, irritation, ulceration. </li></ul></li><li><strong>Systemic adverse effects </strong>— these occur rarely, are much less likely to occur than with oral corticosteroids, and are associated with high doses or prolonged treatment. The risk is higher with drops compared with sprays, as they are administered incorrectly more frequently. </li><li><strong>Systemic adverse effects include:</strong><ul><li>Adrenal suppression — for signs and symptoms of adrenal suppression, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adrenal-insufficiency\">Adrenal insufficiency</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li><li>Cushing's syndrome.</li><li>Decreased bone mineral density.</li><li>Increased intraocular pressure, glaucoma, cataract, blurred vision, central serous chorioretinopathy.<ul><li>If a person presents with symptoms such as blurred vision or other visual disturbances, consider referral to an ophthalmologist for evaluation. </li></ul></li><li>Psychological and behavioural effects (such as psychomotor hyperactivity, sleep disorders, anxiety, depression, and aggression [particularly in children]).</li><li>Growth suppression.</li></ul></li><li>For more information on the systematic adverse effects of corticosteroids, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adverse-effects\">Adverse effects</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li></ul><!-- end field 3d34d20c-4e93-4c8a-9e1c-a74a00f484da --><!-- end item 2b7fc310-196b-4876-bfc9-a74a00f48464 -->","subChapters":[{"id":"5d23be09-6d2c-5b3d-b312-6740e9afb401","slug":"basis-for-recommendation-dcf","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d46d03ff-8640-4f6e-9843-a74a00f484de --><h4>Basis for recommendation</h4><!-- end field d46d03ff-8640-4f6e-9843-a74a00f484de -->","summary":null,"htmlStringContent":"<!-- begin item dcf83c91-142f-4ac4-af69-a74a00f484de --><!-- begin field 45600f2f-86ee-4cc5-8eef-a74a00f484de --><p>This information is largely based on the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>] and the manufacturers' summaries of product characteristics for Flixonase [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019b</a>], Beconase [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019a</a>], and Nasonex [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2020c</a>].</p><h5>Systemic adverse effects</h5><ul><li>The extent of systemic absorption varies between steroids: mometasone furoate and fluticasone have negligible systemic absorption, others have modest absorption, whilst betamethasone has high systemic absorption [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>]. </li><li>The Medicines and Healthcare products Regulatory Agency (MHRA) advises that psychological and behavioural adverse effects of oral corticosteroids may also occur with nasal corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MHRA, 2010</a>].</li><li>Central serous chorioretinopathy has been reported after intranasal administration of corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MHRA, 2017</a>].</li></ul><h5>Ocular adverse effects</h5><ul><li>Manufacturers' summaries of product characteristics list glaucoma and raised intraocular pressure as very rare adverse effects. However, a systematic review and meta-analysis found that inhaled corticosteroids do not lead to clinically significant ocular changes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Valenzuela, 2019</a>].</li><li>A MHRA Drug Saftey update advises that there is a rare risk of central serous chorioretinopathy with local as well as systemic administration of corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MHRA, 2017</a>]. <ul><li>People should be advised to report any blurred vision or other visual disturbances during corticosteroid treatment.</li></ul></li></ul><h5>Intranasal corticosteroids and growth suppression in children</h5><ul><li>Systemic absorption is negligible with mometasone furoate and fluticasone furoate, modest for other corticosteroids, and highest for betamethasone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Scadding, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].<ul><li>Mometasone and fluticasone are favoured for use in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Scadding, 2017</a>].</li></ul></li><li>Several small studies have compared intranasal corticosteroids with placebo in children with allergic rhinitis.<ul><li>These studies show that twice daily beclometasone can slow growth velocity in children, whilst once daily mometasone, triamcinolone, fluticasone, and budesonide do not affect growth. However, it is not known whether once daily beclometasone also affects growth [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Schenkel, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Skoner, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Allen, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Ober, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Murphy, 2006</a>].</li></ul></li><li>However, other studies have shown that, over a 12-month period, the use of once daily fluticasone in children aged 5–8 years (n = 186) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Lee, 2014</a>], and once daily triamcinolone in children aged 3–9 years (n=1078) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Skoner, 2015</a>], may result in a small reduction in growth velocity. </li><li>The height of children receiving prolonged treatment with intranasal corticosteroids should be monitored. If growth suppression is suspected, referral to a paediatrician should be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].</li></ul><!-- end field 45600f2f-86ee-4cc5-8eef-a74a00f484de --><!-- end item dcf83c91-142f-4ac4-af69-a74a00f484de -->","subChapters":[]}]},{"id":"d9a7a884-658c-507d-a1d9-55277ed072ee","slug":"minimizing-adverse-effects","fullItemName":"Minimizing adverse effects","depth":3,"htmlHeader":"<!-- begin field 68bd97f3-9c55-4643-aa41-a74a00f4946a --><h3>How should I minimize the risks of adverse effects in people using intranasal corticosteroids?</h3><!-- end field 68bd97f3-9c55-4643-aa41-a74a00f4946a -->","summary":null,"htmlStringContent":"<!-- begin item 7e73fa21-0389-458b-ac31-a74a00f49455 --><!-- begin field 5743cc57-39b6-4211-b87b-a74a00f4946a --><ul><li><strong>To minimize the adverse effects of intranasal corticosteroids:</strong><ul><li>Prescribe a nasal spray instead of drops. </li><li>Prescribe the weakest potency possible, for the shortest period of time.</li><li>Prescribe a benzalkonium free preparation for people who experience nasal irritation (for example, Flixonase Nasules). </li><li>Provide advice about using the correct <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/intranasal-corticosteroid-treatment/#techniques\">technique</a> to apply corticosteroid drops and sprays.</li></ul></li><li><strong>In children</strong> receiving prolonged treatment with high doses of intranasal corticosteroids (especially drops):<ul><li>Consider prescribing a preparation other than twice daily beclometasone.</li><li>Monitor height regularly, using a growth chart. Any slowing of growth rate should prompt a reduction in dose if possible, or referral to a paediatrician. </li></ul></li></ul><!-- end field 5743cc57-39b6-4211-b87b-a74a00f4946a --><!-- end item 7e73fa21-0389-458b-ac31-a74a00f49455 -->","subChapters":[{"id":"ba7bd3cb-a8ef-53c3-8b0a-cd2dc7a8894c","slug":"techniques","fullItemName":"Techniques","depth":4,"htmlHeader":"<!-- begin field e54d2842-ba6e-4b49-8804-a7a700eed7a4 --><h4>Techniques</h4><!-- end field e54d2842-ba6e-4b49-8804-a7a700eed7a4 -->","summary":null,"htmlStringContent":"<!-- begin item 4e9f91c1-e448-4a7b-9158-a7a700eed541 --><!-- begin field eb15ba79-d013-4aa6-873d-a7a700eed7a4 --><h5>Nasal spray technique</h5><ul><li>Advise the person to:<ul><li>Gently blow the nose to clear it.</li><li>Shake the bottle well and take off the dust cap.</li><li>Close off one nostril and put the nozzle in the other. Tilt the head forward slightly and keep the bottle upright.</li><li>Breathe in slowly through the nose and at the same time squeeze a fine mist into the nose, but avoid sniffing. </li><li>Breathe out through the mouth.</li><li>If two sprays are required in both nostrils, take a second spray in the same nostril then repeat this procedure for the other nostril.</li></ul></li></ul><h5>Nasal drops technique</h5><ul><li>Advise the person to:<ul><li>Gently blow the nose to clear it.</li><li>While standing up, bend right over — if they can not do this, advise them to kneel down and then bend right over.</li><li>Put the opened container into one nostril and gently squeeze.</li><li>Keep squeezing until the sides of the container touch each other — this will mean that about half the dose has been given (about 6 drops).</li><li>Repeat this step to use the remainder in the other nostril.</li><li>Stay with the head down for at least 1 minute after putting the drops in.</li></ul></li><li>If they are unable to manage either of these techniques, advise them instead to:<ul><li>Lie on their back on a bed with the head tilted over the edge.</li><li>Apply the drops.</li><li>Then, rest their head sideways on the bed for at least 1 minute.</li></ul></li></ul><!-- end field eb15ba79-d013-4aa6-873d-a7a700eed7a4 --><!-- end item 4e9f91c1-e448-4a7b-9158-a7a700eed541 -->","subChapters":[]},{"id":"9f1a55a2-27e5-54c3-bf53-8ba0d2892497","slug":"basis-for-recommendation-cd9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f27e05cc-0538-42dd-a627-a74a00f4946e --><h4>Basis for recommendation</h4><!-- end field f27e05cc-0538-42dd-a627-a74a00f4946e -->","summary":null,"htmlStringContent":"<!-- begin item cd9e81a2-0f58-4fc9-9f60-a74a00f4946e --><!-- begin field 1d508bc4-3189-44a3-8856-a74a00f4946e --><p>These recommendations are largely based on the British Society of Allergy and Clinical Immunology (BSACI) <em>BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (revised edition 2017; first edition 2007)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Scadding, 2017</a>], the <em>British National Formulary </em>(BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>], and patient information leaflets for Flixonase Nasules [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2012</a>] and Flixonase Aqueous Nasal Spray [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019d</a>].</p><ul><li>Systemic absorption is negligible with mometasone furoate and fluticasone furoate, modest for other corticosteroids, and highest for betamethasone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Scadding, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].<ul><li>Mometasone and fluticasone are favoured for use in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Scadding, 2017</a>].</li></ul></li><li>The height of children receiving long term intranasal corticosteroids should be monitored. If growth is slowed, treatment should be reviewed and referral to a paediatrician considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].</li></ul><!-- end field 1d508bc4-3189-44a3-8856-a74a00f4946e --><!-- end item cd9e81a2-0f58-4fc9-9f60-a74a00f4946e -->","subChapters":[]}]},{"id":"83766b04-3670-5bb5-abd0-5e9b230172af","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field 96143458-7bd9-4d99-a29a-a74a00f4a952 --><h3>What information and advice should I give to a person receiving intranasal corticosteroids?</h3><!-- end field 96143458-7bd9-4d99-a29a-a74a00f4a952 -->","summary":null,"htmlStringContent":"<!-- begin item 823e7c8a-299e-40fb-be67-a74a00f4a871 --><!-- begin field 8de1d038-c8ae-40b4-a8b7-a74a00f4a952 --><ul><li>Advise the person that: <ul><li>Intranasal corticosteroids should be used regularly, once or twice daily, for effective control of symptoms.</li><li>They may not notice any benefit from the treatment for a few days, and maximal effect may not be apparent until after a few weeks. </li><li>Intranasal corticosteroids (especially drops) should be used correctly to avoid systemic absorption and adverse effects.</li><li>They should stop using the intranasal corticosteroid if they experience local adverse effects (such as nosebleeds or nasal irritation).<ul><li>Treatment can be restarted when adverse effects settle. However, if this occurs regularly, they should seek medical advice.</li></ul></li></ul></li></ul><!-- end field 8de1d038-c8ae-40b4-a8b7-a74a00f4a952 --><!-- end item 823e7c8a-299e-40fb-be67-a74a00f4a871 -->","subChapters":[{"id":"efc3d5ab-b51e-5a71-ae6b-200be002d2ec","slug":"basis-for-recommendation-d1b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 52326d00-99e8-41ea-a6d8-a74a00f4a952 --><h4>Basis for recommendation</h4><!-- end field 52326d00-99e8-41ea-a6d8-a74a00f4a952 -->","summary":null,"htmlStringContent":"<!-- begin item d1b8cdaa-a749-4748-a243-a74a00f4a952 --><!-- begin field 76069ea1-196d-4dec-ab33-a74a00f4a952 --><p>These recommendations are largely based on the British Society of Allergy and Clinical Immunology (BSACI) <em>BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (revised edition 2017; first edition 2007)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Scadding, 2017</a>] and the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].</p><ul><li>The recommendation to stop intranasal corticosteroids if local adverse effects occur, and restart treatment when adverse effects settle, is based on what CKS considers to be good clinical practice.</li></ul><!-- end field 76069ea1-196d-4dec-ab33-a74a00f4a952 --><!-- end item d1b8cdaa-a749-4748-a243-a74a00f4a952 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}